Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations.
作者信息
Peters Katherine B, Geurts Marjolein
机构信息
Department of Neurosurgery, Duke University Medical Center, USA.
Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
出版信息
Neurooncol Pract. 2024 Oct 19;12(Suppl 1):i2-i5. doi: 10.1093/nop/npae076. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations.在异柠檬酸脱氢酶（IDH）突变型胶质瘤患者实用管理的mIDH抑制剂时代即将来临：新药、新证据、新指南及新考量
Neurooncol Pract. 2024 Oct 19;12(Suppl 1):i2-i5. doi: 10.1093/nop/npae076. eCollection 2025 Feb.
2
Symptom management in isocitrate dehydrogenase mutant glioma.异柠檬酸脱氢酶突变型神经胶质瘤的症状管理
Neurooncol Pract. 2024 Oct 19;12(Suppl 1):i38-i48. doi: 10.1093/nop/npae088. eCollection 2025 Feb.
3
Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.异柠檬酸脱氢酶（IDH）突变型神经胶质瘤治疗进展：IDH抑制剂、INDIGO试验的临床意义及未来展望
Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.
4
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.伏立西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。
Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.
5
The Role of Mutant IDH Inhibitors in the Treatment of Glioma.异柠檬酸脱氢酶突变体抑制剂在胶质瘤治疗中的作用。
Curr Neurol Neurosci Rep. 2024 Dec;24(12):631-643. doi: 10.1007/s11910-024-01378-3. Epub 2024 Sep 20.
6
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with -Mutant Glioma.将编辑后的磁共振波谱分析纳入临床实践可能会改善携带突变的胶质瘤患者的护理。
AJNR Am J Neuroradiol. 2025 Jan 8;46(1):113-120. doi: 10.3174/ajnr.A8413.
7
Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.IDH 突变型 glioma 的表观遗传学治疗的系统评价。
World Neurosurg. 2022 Jun;162:47-56. doi: 10.1016/j.wneu.2022.03.051. Epub 2022 Mar 18.
8
Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.成人 IDH 突变型脑桥胶质瘤的临床转归、影像学表现和遗传学特征。
Acta Neurochir (Wien). 2024 Jun 12;166(1):263. doi: 10.1007/s00701-024-06154-3.
9
Who will benefit from vorasidenib? Review of data from the literature and open questions.谁将从vorasidenib中获益？文献数据综述与未解决的问题。
Neurooncol Pract. 2024 Nov 14;12(Suppl 1):i6-i18. doi: 10.1093/nop/npae104. eCollection 2025 Feb.
10
Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.异柠檬酸脱氢酶抑制剂在急性髓系白血病患者中的疗效和耐受性：临床试验的系统评价。
Leuk Res. 2023 Jun;129:107077. doi: 10.1016/j.leukres.2023.107077. Epub 2023 Apr 14.
引用本文的文献
1
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.胶质瘤中突变异柠檬酸脱氢酶的靶向治疗：一项系统评价
Cancers (Basel). 2025 Aug 12;17(16):2630. doi: 10.3390/cancers17162630.
本文引用的文献
1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
2
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.沃拉西尼布和伊沃西尼布治疗 IDH1 突变型低级别胶质瘤：一项随机、围手术期的 1 期临床试验。
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
3
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.美国 2015-2019 年确诊的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202.
4
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.在复发性或进行性 IDH1 突变型神经胶质瘤患者中进行的脑穿透性突变 IDH1 抑制剂 DS-1001 的首次人体 I 期研究。
Neuro Oncol. 2023 Feb 14;25(2):326-336. doi: 10.1093/neuonc/noac155.
5
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.奥拉替尼（FT-2102）治疗复发性或难治性 IDH1 突变型神经胶质瘤患者的多中心、开放标签、Ib/II 期研究。
Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139.
6
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
7
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.沃拉西尼布，一种 IDH1/2 突变体的双重抑制剂，用于复发性或进行性脑胶质瘤；一项首次人体 I 期试验的结果。
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.
8
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma.ivosidenib 治疗异柠檬酸脱氢酶 1 突变型高级别胶质瘤
J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12.
9
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
10
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.放疗联合丙卡巴肼、洛莫司汀和长春新碱治疗低级别胶质瘤
N Engl J Med. 2016 Apr 7;374(14):1344-55. doi: 10.1056/NEJMoa1500925.
Zotero 插件